Sign In
Buy AMGN
$338.22
+9.96 (+3.03%)
At Close: Jun 03, 2026
Advisors Capital Management LLC Purchases 4,326 Shares of Amgen Inc. $AMGN
03:13am, Friday, 14'th Nov 2025
Advisors Capital Management LLC boosted its holdings in Amgen Inc. (NASDAQ: AMGN) by 6.7% during the undefined quarter, according to the company in its most recent filing with the SEC. The institution
Why Amgen Stock Edged Past the Market on Thursday
05:36pm, Thursday, 13'th Nov 2025
It appears that some investors took a pair of new and bullish pundit takes to heart. One of the pair was a famous stock picker who appears regularly on TV.
Trade Tracker: Bill Baruch buys more Amgen
01:54pm, Thursday, 13'th Nov 2025
Bill Baruch, founder and president at Blue Line Capital, joins CNBC's “Halftime Report” to detail his latest Amgen purchase. The Investment Committee debate the biotech sector.
Cramer's Stop Trading: Amgen
10:30am, Thursday, 13'th Nov 2025
Jim Cramer breaks down why he's keeping an eye on shares of Amgen.
Why Amgen Stock Was a Nearly 5% Winner Today
05:31pm, Tuesday, 11'th Nov 2025
An analyst bumped his price target higher on the shares. He didn't change his recommendation, however.
Three Healthcare Buys That Wall Street Loves
10:50am, Tuesday, 11'th Nov 2025
New technologies and an aging population are lifting the healthcare sector. Immunotherapy and anti-obesity drugs are leading the way.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Tuesday, 11'th Nov 2025
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Amgen CEO talks trial results of cardiac drug Repatha
07:40pm, Monday, 10'th Nov 2025
Amgen Chairman, President and CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk quarterly results, its recent drug trials, what is ahead for the company and more.
Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%
02:30pm, Saturday, 08'th Nov 2025
Merck said Saturday its new pill — a potential rival to Regeneron and Amgen — lowered stubbornly high cholesterol by almost 60%.
AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL
10:15am, Saturday, 08'th Nov 2025
Study Also Shows 36% Reduction in Risk of Heart Attack Repatha is the First and Only PCSK9 Inhibitor to Significantly Reduce the Risk of First Heart Attack and Stroke THOUSAND OAKS, Calif. , Nov. 8,
Amgen cholesterol drug cuts risk of first cardiac event by 25%
10:11am, Saturday, 08'th Nov 2025
Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients who have never had a heart attack or stroke, according to results from a lar
Amgen: Buy This Cheap Biotech Leader
12:11am, Saturday, 08'th Nov 2025
Amgen is a biotech leader with strong sales growth, key products outperforming, and an impressive R&D pipeline fueling future prospects. Despite political headwinds and margin pressures, AMGN raised f
Amgen Stock: New All-Time Highs Ahead After Earnings Beat
12:19pm, Friday, 07'th Nov 2025
Amgen Inc. NASDAQ: AMGN just delivered a strong beat-and-raise quarter. That's pushed the stock to within striking distance of its 52-week high.
Stock Of The Day: Will Amgen Reverse Again?
10:41am, Thursday, 06'th Nov 2025
Amgen Inc. (NASDAQ:AMGN) is lower on Thursday. Yesterday, the shares gained almost 8% after the company released earnings.
Why Amgen Stock Was Crushing It on Wednesday
02:26pm, Wednesday, 05'th Nov 2025
The biotech and pharmaceutical mainstay posted its third-quarter results. It was a beat-and-raise quarter that featured double-digit growth on the top line.
